STOCK OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 06, 2023 |
Aug. 11, 2023 |
Mar. 31, 2024 |
Dec. 27, 2023 |
Dec. 17, 2023 |
Apr. 16, 2023 |
Feb. 15, 2023 |
Oct. 30, 2022 |
Sep. 30, 2022 |
Sep. 16, 2022 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
| Subsidiary, Sale of Stock [Line Items] | |||||||||||||
| Stock option expense | $ 152,339 | $ 167,573 | |||||||||||
| Unamortized option expense | $ 1,137,358 | $ 1,137,358 | |||||||||||
| Unamortized option expense expected to be recognized over a weighted average period | 11 months 1 day | ||||||||||||
| Number of aggregate shares granted | 100,000 | ||||||||||||
| Fair value of all restricted shares | $ 220,000 | ||||||||||||
| Number of warrants issued | |||||||||||||
| Weighted average exercise price | $ 2.92 | $ 2.92 | $ 4.68 | ||||||||||
| Warrant expense | $ 3,081,400 | $ 4,187,800 | $ 167,573 | ||||||||||
| Proceeds from warrant exercised | $ 4,800,000 | $ 400,000 | |||||||||||
| Lender Agreement [Member] | |||||||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||||||
| Warrants description | On April 16, 2023 in conjunction with an agreement with certain lenders, the Company issued warrants to purchase up to 1,000,000 shares of the Company’s common stock with an exercise price of $3.00 per share, and warrants to purchase up to 250,000 shares of our common stock with an exercise price of $4.00 per share. All of these warrants have a term of 5 years and expire in April of 2028. Under this agreement, these lenders would be required to exercise all or a portion of these warrants if the Company’s common stock traded at prices between $3.00 per share and $4.00 per share for a prescribed number of trading days. On June 19, 2023, this agreement was modified to convert all of related outstanding debt in exchange for a reduction in the exercise price of all of these warrants to $2.50 per share. | ||||||||||||
| Non-cash financing expenses | $ 259,074 | ||||||||||||
| Officers and directors [Member] | IPO [Member] | |||||||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||||||
| Number of warrants issued | 695,000 | ||||||||||||
| Weighted average exercise price | $ 4.20 | ||||||||||||
| WP | 5 years | ||||||||||||
| Underwriter [Member] | |||||||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||||||
| Number of warrants issued | 135,000 | ||||||||||||
| Maxim [Member] | Private Placement [Member] | |||||||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||||||
| Number of warrants issued | 32,000 | ||||||||||||
| Weighted average exercise price | $ 4.40 | ||||||||||||
| WP | 5 years | ||||||||||||
| Third-party Investor [Member] | |||||||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||||||
| Number of warrants issued | 920,000 | 366,562 | 352,188 | 517,500 | |||||||||
| Weighted average exercise price | $ 4.00 | $ 4.00 | $ 4.00 | $ 4.00 | |||||||||
| Shareholders [Member] | |||||||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||||||
| Number of warrants issued | 2,000,000 | ||||||||||||
| Weighted average exercise price | $ 4.00 | ||||||||||||
| Warrant expense | $ 4,939,000 | ||||||||||||
| Warrant Holders [Member] | |||||||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||||||
| Number of warrants issued | 1,000,000 | 2,000,000 | |||||||||||
| Weighted average exercise price | $ 5.50 | $ 5.00 | |||||||||||
| Number of warrants exercised | 500,000 | 1,000,000 | |||||||||||
| Proceeds from warrant exercised | $ 2,000,000 | $ 4,000,000 | |||||||||||
| Unvested Restricted Shares [Member] | |||||||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||||||
| Unrecognized compensation cost | $ 166,500 | $ 166,500 | |||||||||||